Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review

被引:105
作者
McGinty, Emma E. [1 ,2 ]
Baller, Julia [1 ,2 ]
Azrin, Susan T. [3 ]
Juliano-Bult, Denise [3 ]
Daumit, Gail L. [4 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 359, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA
[3] NIMH, Bethesda, MD 20892 USA
[4] Johns Hopkins Med Inst, Div Gen Internal Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA
关键词
intervention; schizophrenia; medical; somatic; obesity; tobacco; INDUCED WEIGHT-GAIN; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; LIFE-STYLE INTERVENTION; OLANZAPINE-TREATED PATIENTS; BUPROPION SUSTAINED-RELEASE; TYPE-2; DIABETES-MELLITUS; OBSTRUCTIVE SLEEP-APNEA; DOUBLE-BLIND; SMOKING-CESSATION;
D O I
10.1093/schbul/sbv101
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
People with serious mental illness (SMI) have mortality rates 2 to 3 times higher than the overall US population, largely due to cardiovascular disease. The prevalence of cardiovascular risk factors such as obesity and diabetes mellitus and other conditions, such as HIV/AIDS, is heightened in this group. Based on the recommendations of a National Institute of Mental Health stakeholder meeting, we conducted a comprehensive review examining the strength of the evidence surrounding interventions to address major medical conditions and health-risk behaviors among persons with SMI. Peer-reviewed studies were identified using 4 major research databases. Randomized controlled trials and observational studies testing interventions to address medical conditions and risk behaviors among persons with schizophrenia and bipolar disorder between January 2000 and June 2014 were included. Information was abstracted from each study by 2 trained reviewers, who also rated study quality using a standard tool. Following individual study review, the quality of the evidence (high, medium, low) and the effectiveness of various interventions were synthesized. 108 studies were included. The majority of studies examined interventions to address overweight/obesity (n = 80). The strength of the evidence was high for 4 interventions: metformin and behavioral interventions had beneficial effects on weight loss; and bupropion and varenicline reduced tobacco smoking. The strength of the evidence was low for most other interventions reviewed. Future studies should test long-term interventions to cardiovascular risk factors and health-risk behaviors. In addition, future research should study implementation strategies to effectively translate efficacious interventions into real-world settings.
引用
收藏
页码:96 / 124
页数:29
相关论文
共 184 条
[1]   Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial [J].
Afshar, H. ;
Roohafza, H. ;
Mousavi, G. ;
Golchin, S. ;
Toghianifar, N. ;
Sadeghi, M. ;
Talaei, M. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (02) :157-162
[2]   Obesity Among Those with Mental Disorders A National Institute of Mental Health Meeting Report [J].
Allison, David B. ;
Newcomer, John W. ;
Dunn, Andrea L. ;
Blumenthal, James A. ;
Fabricatore, Anthony N. ;
Daumit, Gail L. ;
Cope, Mark B. ;
Riley, William T. ;
Vreeland, Betty ;
Hibbeln, Joseph R. ;
Alpert, Jonathan E. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2009, 36 (04) :341-350
[3]   Non-pharmacological management of anti psychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials [J].
Alvarez-Jimenez, Mario ;
Hetrick, Sarah E. ;
Gonzalez-Blanch, Cesar ;
Gleeson, John F. ;
McGorry, Patrick D. .
BRITISH JOURNAL OF PSYCHIATRY, 2008, 193 (02) :101-107
[4]   Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial [J].
Alvarez-Jimenez, Mario ;
Martinez-Garcia, Obdulia ;
Perez-Iglesias, Rocio ;
Luz Ramirez, Mari ;
Luis Vazquez-Barquero, Jose ;
Crespo-Facorro, Benedicto .
SCHIZOPHRENIA RESEARCH, 2010, 116 (01) :16-19
[5]   The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients [J].
Amrami-Weizman, Avi ;
Maayan, Rachel ;
Gil-Ad, Irit ;
Pashinian, Artashez ;
Fuchs, Camil ;
Kotler, Moshe ;
Poyurovsky, Michael .
PSYCHOPHARMACOLOGY, 2013, 230 (01) :23-27
[6]  
[Anonymous], HLTH HOM ENR CHRON C
[7]  
[Anonymous], 2013, AHRQ PUBLICATION
[8]   Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice [J].
Appel, Lawrence J. ;
Clark, Jeanne M. ;
Yeh, Hsin-Chieh ;
Wang, Nae-Yuh ;
Coughlin, Janelle W. ;
Daumit, Gail ;
Miller, Edgar R., III ;
Dalcin, Arlene ;
Jerome, Gerald J. ;
Geller, Steven ;
Noronha, Gary ;
Pozefsky, Thomas ;
Charleston, Jeanne ;
Reynolds, Jeffrey B. ;
Durkin, Nowella ;
Rubin, Richard R. ;
Louis, Thomas A. ;
Brancati, Frederick L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (21) :1959-1968
[9]   Nizatidine for the treatment of patients with quetiapine-induced weight gain [J].
Atmaca, M ;
Kuloglu, M ;
Tezcan, E ;
Ustundag, B ;
Kilic, N .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (01) :37-40
[10]   The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: results from a national multicentric study [J].
Attux, Cecilia ;
Martini, Larissa C. ;
de Araujo, Celia Maria ;
Roma, Ana Maria ;
Reis, Andre F. ;
Bressan, Rodrigo A. .
REVISTA BRASILEIRA DE PSIQUIATRIA, 2011, 33 (02) :117-121